Back

Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH

Read More

Back

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Read More

Back

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Read More

Back

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Read More

Back

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Read More

Back

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Read More

Back

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Read More

Back

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

Read More

Back

Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

Read More

Back

Salarius Pharmaceuticals CEO Issues Letter to Stockholders

Read More